Drug Trial Radar · NCT07556913
Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3
Planned (sponsor's estimate)
Start
Jul 29, 2026
Primary completion
Jan 31, 2039
Study completion Jan 31, 2039
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- Female only
Summary
As written by the sponsor on the registry.
The study will include participants who were exposed to at least one dose of elafibranor either within the three weeks before conception or at any time during pregnancy (based on estimated last menstrual period \[LMP\]). Information will be collected from participants, their healthcare providers, published studies, and safety databases. Reports of pregnancy linked to elafibranor from clinical trials, spontaneous reports, or literature will also be included, with steps taken to avoid duplicates. The study begins once the first participant is enrolled and ends after the last mother and child data are collected. It is planned to run for about 10 years, with infant follow-up lasting up to 2 years, for a maximum total duration of 12 years and 9 months. The program is strictly observational. All medical care, visit schedules, and treatment decisions remain with healthcare providers. Only routine medical record data will be collected, and no extra tests or procedures are required. Participation is voluntary, and written informed consent will be obtained before enrollment.
Conditions
- Pregnancy Related
Interventions
ElafibranorDrug
The medicinal product elafibranor is prescribed in the usual manner in accordance with the terms of the marketing authorization of the participants' country.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Prevalence of congenital malformations at birthTime frame: At birth
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Virtual Research Coordination Center
Wilmington, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.